Pharmacological properties : תכונות פרמקולוגיות

Pharmacodynamic Properties

5.1. Pharmacodynamic properties
Pharmacotherapeutic group: Non-water-soluble X-ray contrast media; ATC code: V08AD01 When used in conventional chemoembolisation by selective hepatic intra-arterial injection, LIPIODOL ULTRA-FLUID allows, as an oily contrast agent, to visualise and control the procedure thanks to its opacifying properties; as a vehicle, to carry and elute anticancer drugs into hepatocellular carcinoma nodules; and as an agent of transient embolism, to contribute to the vascular embolisation induced during the procedure.
As it is a selective procedure by hepatic intra-arterial injection, conventional chemoembolisation combines the effect of a loco-regional targeted anticancer drug with the effect of an ischemic necrosis induced by dual arterio-portal embolisation. The opacifying properties and the tropism for hepatic tumours of LIPIODOL ULTRA-FLUID make it possible to perform post procedure imaging for several months to ensure effective monitoring of the patient.

Pharmacokinetic Properties

5.2. Pharmacokinetic properties
After intralymphatic injection
LIPIODOL ULTRA-FLUID is released into the blood and captured by the liver and lungs, where the lipid droplets are broken down in the pulmonary alveoli, spleen and adipose tissue.
After being taken up by the tissues and storage organs, resorption varies from a few days to several months or years. It is continuous and regular and it is possible to detect the presence of iodine in the urine as long as an opaque mark persists on imaging.
After selective intra-arterial injection
Iodine remains primarily eliminated in the urine. After selective injection into the hepatic artery for the diagnosis of liver damage or after transarterial chemoembolisation of hepatocellular carcinomas, LIPIODOL ULTRA-FLUID is significantly more concentrated in the tumour than in surrounding healthy liver tissue.